HANXBIO-B repurchases 53,100 H-shares for HKD 1.44 million, cutting free float by 0.04%

Bulletin Express06-03

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buyback executed on 3 June 2026, reducing its outstanding H-share count and increasing treasury holdings.

The company repurchased 53,100 H-shares on the Hong Kong Stock Exchange at prices ranging between HKD 26.00 and HKD 27.66 per share, with a volume-weighted average of HKD 27.03. The transaction totalled HKD 1.44 million.

Following the buyback: • Issued shares (excluding treasury shares) declined to 135.24 million from 135.29 million, a 0.039% reduction. • Treasury shares rose to 978,000 from 924,900. • Total issued shares (including treasury stock) remained unchanged at 136.22 million.

The purchase was made under the repurchase mandate approved on 12 February 2026, which authorises up to 13.62 million shares for buyback. Cumulative repurchases under this mandate now stand at 978,000 shares, equivalent to 0.72% of the company’s issued share capital at the mandate date.

In accordance with Hong Kong listing regulations, HANXBIO-B is subject to a 30-day moratorium on issuing new shares or transferring treasury shares, effective until 3 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196015772?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196015772","market":"hk","top_or_hot":-1,"title":"HANXBIO-B repurchases 53,100 H-shares for HKD 1.44 million, cutting free float by 0.04%","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buyback executed on 3 June 2026, reducing its outstanding H-share count and increasing treasury holdings.</p>\n<p>The company repurchased 53,100 H-shares on the Hong Kong Stock Exchange at prices ranging between HKD 26.00 and HKD 27.66 per share, with a volume-weighted average of HKD 27.03. The transaction totalled HKD 1.44 million.</p>\n<p>Following the buyback:\n• Issued shares (excluding treasury shares) declined to 135.24 million from 135.29 million, a 0.039% reduction.  \n• Treasury shares rose to 978,000 from 924,900.  \n• Total issued shares (including treasury stock) remained unchanged at 136.22 million.</p>\n<p>The purchase was made under the repurchase mandate approved on 12 February 2026, which authorises up to 13.62 million shares for buyback. Cumulative repurchases under this mandate now stand at 978,000 shares, equivalent to 0.72% of the company’s issued share capital at the mandate date.</p>\n<p>In accordance with Hong Kong listing regulations, HANXBIO-B is subject to a 30-day moratorium on issuing new shares or transferring treasury shares, effective until 3 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B repurchases 53,100 H-shares for HKD 1.44 million, cutting free float by 0.04%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B repurchases 53,100 H-shares for HKD 1.44 million, cutting free float by 0.04%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-03 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buyback executed on 3 June 2026, reducing its outstanding H-share count and increasing treasury holdings.</p>\n<p>The company repurchased 53,100 H-shares on the Hong Kong Stock Exchange at prices ranging between HKD 26.00 and HKD 27.66 per share, with a volume-weighted average of HKD 27.03. The transaction totalled HKD 1.44 million.</p>\n<p>Following the buyback:\n• Issued shares (excluding treasury shares) declined to 135.24 million from 135.29 million, a 0.039% reduction.  \n• Treasury shares rose to 978,000 from 924,900.  \n• Total issued shares (including treasury stock) remained unchanged at 136.22 million.</p>\n<p>The purchase was made under the repurchase mandate approved on 12 February 2026, which authorises up to 13.62 million shares for buyback. Cumulative repurchases under this mandate now stand at 978,000 shares, equivalent to 0.72% of the company’s issued share capital at the mandate date.</p>\n<p>In accordance with Hong Kong listing regulations, HANXBIO-B is subject to a 30-day moratorium on issuing new shares or transferring treasury shares, effective until 3 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1196015772","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196015772","pubTimestamp":1780487037,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buyback executed on 3 June 2026, reducing its outstanding H-share count and increasing treasury holdings. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"瀚讯生物-B以144万港元回购5.31万股H股自由流通量削减0.04%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share buyback executed on 3 June 2026, reducing its outstanding H-share count and increasing treasury holdings.\nThe company repurchased 53,100 H-shares on the Hong Kong Stock Exchange at prices ranging between HKD 26.00 and HKD 27.66 per share, with a volume-weighted average of HKD 27.03. The transaction totalled HKD 1.44 million.\nFollowing the buyback:\n• Issued shares (excluding treasury shares) declined to 135.24 million from 135.29 million, a 0.039% reduction.  \n• Treasury shares rose to 978,000 from 924,900.  \n• Total issued shares (including treasury stock) remained unchanged at 136.22 million.\nThe purchase was made under the repurchase mandate approved on 12 February 2026, which authorises up to 13.62 million shares for buyback. Cumulative repurchases under this mandate now stand at 978,000 shares, equivalent to 0.72% of the company’s issued share capital at the mandate date.\nIn accordance with Hong Kong listing regulations, HANXBIO-B is subject to a 30-day moratorium on issuing new shares or transferring treasury shares, effective until 3 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196015772","isCrawlerRequest":true}